MAYO CLINIC LABORATORIES

FILE DEFINITION TEST CHANGE

Notification Date: September 23, 2022
Effective Date: October 24, 2022

Reanalysis of Acute Myeloid Leukemia 4- or 11- Gene Panels, Additional Genes

Test ID: NGSFX

Explanation: Changes to the following will occur on the above effective date: naming convention, genes evaluated, report available time, days performed, and reorganization of the method description.

Current Reporting Name
Reflex Analysis, NGSHM

New Reporting Name
Reanalysis, AML 4 or 11 Gene Panel

Current Published Name
Next-Generation Sequencing, Reflex from Acute Myeloid Leukemia 4- or 11-Gene Panels, Varies

New Published Name
Reanalysis of Acute Myeloid Leukemia 4- or 11-Gene Panels, Additional Genes

Current Genetics Information
This test includes next-generation sequencing to evaluate for 42 genes and select intronic regions.

New Genetics Information
This test includes next-generation sequencing to evaluate for 47 genes and select intronic regions. Genes added: BCORL1, BRAF, NF1, PPM1D STAT3, UBA1 Gene removed: SRP72

Current Report Available
14 to 21 days

New Report Available
16 to 21 days

Current Days Performed
Monday, Wednesday, Friday

New Days Performed
Monday through Friday

Current Method Description	New Method Description
This analysis requires a next-generation sequencing panel be previously performed at Mayo Clinic Laboratories within the last 6 months (NGAMT / Next-Generation Sequencing Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel [FLT3, IDH1, IDH2, TP53], Varies or NGAML / Next-Generation Sequencing, Acute Myeloid Leukemia, 11-Gene Panel, Varies). An extended bioinformatics analysis is performed on the original data by a bioinformatics pipeline and a variant call file is generated for final analysis and reporting of any additional pathogenic variants within genomic target regions present in the larger NGSHM / OncoHeme Next-Generation Sequencing for Myeloid Neoplasms, Varies.(Unpublished Mayo method)	This analysis requires either NGAMT / Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next-Generation Sequencing Varies or NGAML / Acute Myeloid Leukemia, 11-Gene Panel, Varies to have been previously performed at Mayo Clinic Laboratories within the last 6 months. An extended bioinformatics analysis is performed on the original data by a bioinformatics pipeline, and a variant call file is generated for final analysis and reporting of any additional disease-causing variants within genomic target regions present in the larger NGSHM / Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation, Varies.(Unpublished Mayo method)

Questions

Contact Connie Penz, Laboratory Technologist Resource Coordinator at 800-533-1710.